3 Stocks Conceivably Priced Below Fair Value

In recent weeks, global markets have demonstrated resilience amidst geopolitical tensions and fluctuating oil prices, with major indices like the S&P 500 posting significant gains driven by robust corporate earnings. As central banks hold interest rates steady amid economic uncertainties, investors are keenly focused on identifying opportunities that may be priced below their intrinsic value. In this context, a good stock is often characterized by strong fundamentals and the potential for growth despite prevailing market volatility.

Top 10 Undervalued Stocks Based On Cash Flows

Click here to see the full list of 437 stocks from our Undervalued Global Stocks Based On Cash Flows screener.

Let’s take a closer look at a couple of our picks from the screened companies.

Overview: Avary Holding(Shenzhen)Co., Limited designs, develops, manufactures, and sells printed circuit boards across China, the United States, the rest of Asia, and Europe with a market cap of CN¥166.33 billion.

Operations: Avary Holding(Shenzhen)Co., Limited generates revenue through the design, development, manufacture, and sale of printed circuit boards in China, the United States, other parts of Asia, and Europe.

Estimated Discount To Fair Value: 35.8%

Avary Holding is trading at 35.8% below its estimated fair value, with shares priced at CNY 72.05 compared to a future cash flow value of CNY 112.3. Despite recent earnings showing a slight decline in net income to CNY 462.74 million for Q1 2026, the company is expected to grow earnings significantly by over 20% annually in the next three years, surpassing the broader Chinese market’s revenue growth forecast of 15.5%.

Overview: Risen Energy Co., Ltd. designs, develops, manufactures, and sells solar modules in China with a market cap of CN¥19.90 billion.

Operations: Risen Energy Co., Ltd. primarily generates its revenue through the design, development, manufacturing, and sale of solar modules in China.

Estimated Discount To Fair Value: 34.4%

Risen Energy is trading at CN¥17.74, significantly below its future cash flow value of CN¥27.04, offering potential undervaluation based on discounted cash flow analysis. Despite a volatile share price and recent earnings showing a net loss of CN¥361.03 million for Q1 2026, the company is projected to achieve profitability within three years with revenue growth forecasted at 22.5% annually, outpacing the Chinese market’s anticipated growth rate of 15.6%.

Overview: Caliway Biopharmaceuticals Co., Ltd. develops drugs for aesthetic medicine and chronic inflammation, with a market capitalization of NT$161.86 billion.

Operations: Caliway Biopharmaceuticals Co., Ltd.’s revenue is primarily derived from its drug development activities in the fields of aesthetic medicine and chronic inflammation.

Estimated Discount To Fair Value: 35.2%

Caliway Biopharmaceuticals, trading at NT$105, is undervalued compared to its future cash flow value of NT$161.98. Despite lacking meaningful revenue (NT$38M) and a volatile share price, Caliway’s earnings are forecasted to grow significantly at 119.92% annually, with expectations of profitability within three years. The company’s innovative CBL-514 drug candidate is advancing through pivotal Phase 3 trials for fat reduction, enhancing its clinical data foundation and market potential amidst ongoing regulatory progress.

Turning Ideas Into Actions

Curious About Other Options?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SZSE:002938 SZSE:300118 and TWSE:6919.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com